Key facts
- This page summarizes Jotin Marango's Form 4 filing for ImageneBio, Inc. (IKNA).
- 5 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 29 Jul 2025, 21:32.
Jotin Marango - 25 Jul 2025 Form 4 Insider Report for ImageneBio, Inc. (IKNA)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- IKNA
- Reported as of
- 25 Jul 2025
- Net transaction value
- -$79,451
- SEC form
- 4
- Accepted by SEC
- 29 Jul 2025, 21:32:38 UTC
- Prior SEC filing
- 02 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jotin Marango
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jotin Marango filed Form 4 for ImageneBio, Inc. (IKNA) on 29 Jul 2025.
Change
- Previous filing in this sequence was filed on 02 Feb 2024.
- Current net transaction value: -$79,451.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001777513
Primary reporting owner
Marango Jotin
- Relationship
- Chief Financial Officer
- Address
- IMAGENEBIO, INC., 645 SUMMER STREET, SUITE 101, BOSTON
- Signature
- /s/ Jotin Marango
- Signature date
- 29 Jul 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IMA
transaction
Common Stock
Award
- Transaction value
- Shares
- +15,776
- Change %
- Price
- Shares after
- 15,776
- Date
- 28 Jul 2025
- Ownership
- Direct
- Footnotes
- F1
IMA
transaction
Common Stock
Tax liability
- Transaction value
- $79,451
- Shares
- -4,630
- Change %
- -29%
- Price
- $17.16
- Shares after
- 11,146
- Date
- 28 Jul 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IMA
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -181,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 25 Jul 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 181,000
- Exercise price
- Footnotes
- F1
IMA
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -105,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 25 Jul 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 105,000
- Exercise price
- Footnotes
- F1
IMA
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -397,199
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 25 Jul 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 397,199
- Exercise price
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Jotin Marango is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
In connection of the closing of the Merger between the Company (formerly known as Ikena Oncology, Inc. ("Ikena")) and Inmagene Biopharmaceuticals, shares of the combined company were issued on July 28 in exchange for certain options held by the holder in Ikena.